1Ren J,Singh BN,Huang Q,et al.DNA hypermethylation as a chemotherapy target[J].Cell Signal,2011,23(7):1082-1093.
2Cechova H,Lassuthova P,Novakova T,et al.Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia[J].Neoplasma,2012,59(2):168-174.
5Lukina AE, Bariakh EA, Kravchenko SK, et al. Successful treatment of a patient with two hematologic tumors: double-hit lymphoma and acute myelomonoblastic leukemia[J].Ter Arkh,2014,86(7):80-84.
6Polednak AP. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries[J]. J Registry Manag,2014,41(2):77-84.
7Trotti A, Byhardt R, Stetz J, et al.Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment : impact on radiotherapy[J].Int J Radiat Oncol Biol Phys,2000,47 ( 1 ) : 13-47.
8Sauntararajah Y,Sekeres M,Advani A,et al.Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes[J].J Clin Invest,2015,125(3):1043-1055.
9Liu Y,Tabarroki A,Billings S.Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet's syndrome that was refractory to 5-azacitidine[J].Leuk Lymphoma,2014,55(2):447-449.
10Tawbi HA,Beumer JH,Tarhini AA,et al.Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma:a phaseⅠ/Ⅱstudy and pharmacokinetic analysis[J].Ann Oncol,2013,24(4):1112-1119.
